Bicycle Therapeutics reports Q2 2026 pipeline progress, cash into 2030

Bicycle Therapeutics plc reported second quarter 2026 results and business updates on July 30, 2026. The company said it is actively enrolling patients in a Phase 2 trial evaluating nuzefatide in adult patients with recurrent pancreatic ductal adenocarcinoma, with the first patient dosed in April 2026 at the 8mg/m2 Q2W preferred dose.¹

At the AACR Annual Meeting 2026, the company presented data from a Phase 1/2 trial of nuzefatide 6.5mg/m2 once every two weeks plus nivolumab 480mg once every four weeks in 14 patients with metastatic urothelial cancer who had previously progressed on a checkpoint inhibitor, showing a differentiated safety profile and promising anti-tumor activity, as of a February 9, 2026 data cutoff.¹ Preclinical work also showed EphA2 expression in all 16 pancreatic cancer patient-derived xenograft models tested, with 10 of 14 assessed models sensitive to nuzefatide.¹

At the 2026 ASCO meeting, the company presented interim Duravelo-2 data on zelenectide pevedotin, targeting Nectin-4. At the data cutoff of July 23, 2025, Bicycle reached regulatory alignment on the zelenectide 6mg dose as optimal, with results showing a 65% overall response rate regardless of confirmation and a BICR-confirmed ORR of 58% at the 27-week cutoff.¹ A later confirmed response brought the BICR-confirmed ORR to 62%.¹ Updated Duravelo-1 data as of August 1, 2025 in cisplatin-ineligible patients showed a 59% ORR regardless of confirmation, 50% confirmed ORR, an 82% disease control rate, and median progression-free survival of 13.0 months.¹

The company also said it remains on track to begin the Phase 1 trial for BT1702, its MT1-MMP targeting Bicycle Radioconjugate, in 2027.¹ Bicycle added Thomas Powles, Professor of Genitourinary Oncology and Director of Barts Cancer Centre, to its Clinical Advisory Board.¹

Financially, cash and cash equivalents were $510.1 million as of June 30, 2026, with cash runway expected into 2030.¹ Cash declined from $628.1 million as of December 31, 2025.¹